Last update July 14, 2015

Polymixin E


Safe substance and/or breastfeeding is the best option.

Pharmacokinetic data (high volume of distribution and molecular weight) would explain the minimal excretion into breast milk mentioned in two older reports.

Due to a poor oral bioavailability, appearance in the infant's plasma from ingested milk is regarded as nil or scanty, except in premature infants or during the immediate neonatal period who may show an increased intestinal absorption.


We do not have alternatives for Polymixin E since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Polymixin E is also known as Colistin. Here it is a list of alternative known names::


Main tradenames from several countries containing Polymixin E in its composition:


Variable Value Unit
Oral Bioavail. 0 %
Molecular weight 1750 daltons
Protein Binding 50 %
VD 190 l/Kg
Tmax 1 - 7 hours
1.5 - 4 hours
M/P ratio 0.2 -
Theoretical Dose < 0.17 mg/Kg/d
Relative Dose < 3 %
Ped.Relat.Dose < 3 %


  1. Middleton PG, Gade EJ, Aguilera C, MacKillop L, Button BM, Coleman C, Johnson B, Albrechtsen C, Edenborough F, Rigau D, Gibson PG, Backer V. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. Eur Respir J. 2020 Feb 6;55(2). pii: 1901208. Abstract Full text (link to original source) Full text (in our servers)
  2. LactMed. Colisitn. Full Record Display. 2015 Full text (in our servers)
  3. José de Jesús Coria Lorenzo, Alfredo Morayta Ramírez, Yetzamin Gutiérrez Muñoz. Polimixinas en la era de la multidrogorresistencia. Revista de Enfermedades Infecciosas en Pediatría 2011;25(98):66-70. 2011 Full text (in our servers)
  4. Luque S, Grau S, Berenguer N, Horcajada JP, Sorlí L, Montero MM, Salas E. [Shedding light on the use of colistin: still gaps to be filled]. Enferm Infecc Microbiol Clin. 2011 Abstract Full text (in our servers)
  5. Ratjen F, Rietschel E, Kasel D, Schwiertz R, Starke K, Beier H, van Koningsbruggen S, Grasemann H. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother. 2006 Abstract
  6. Li J, Coulthard K, Milne R, Nation RL, Conway S, Peckham D, Etherington C, Turnidge J. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother. 2003 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM